American Journal of Hematology
American Journal of Hematology
5 years ago

Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission

Liisa Volin, Anne Huynh, Depei Wu, , Mohamad Mohty, Mohamed Houhou, Myriam Labopin, Arnon Nagler, Norbert-Claude Gorin, Ibrahim Yakoub-Agha, Jean Yves Cahn, Peter Remenyi, Melanie Mercier, Thomas Pabst
Patients with Acute Myelogenous Leukemia have a better outcome if reaching molecular remission. We compared the outcome of 373 patients autografted and 335 patients allografted with a 10/10 compatible unrelated donor in first molecular remission. Patients were stratified using the ELN European Leukemia Net classification. ELN favorable group: (234 auto and 70 unrelated transplants). By univariate analysis, in the auto group, the Non Relapse Mortality (NRM) was lower (3.7% versus 19%; p< 10−4), Relapse Incidence (RI) higher (29% versus 17%, p< 10−4), Leukemia Free Survival (LFS) identical (67% versus 64%) and Overall Survival (OS) better than in the allogeneic group (83% versus 62%; p=0.008). By multivariate analysis, autologous transplantation was associated with a lower NRM (HR: 4, p =0.01) and a better OS (HR: 2.08, p= 0.04). ELN intermediate group 1: (87 autologous and 172 unrelated transplants). By univariate analysis, in the auto group, NRM was lower (2.5% versus 11.8%; p= 0.03), RI higher (59% versus 18%, p< 10−6), LFS lower (39% versus 70%; p< 10−6) and OS lower than in the unrelated donor group (61% versus 74%; p=0.005). By multivariate analysis, unrelated donor was superior to autologous transplantation for LFS (HR: 0.36, p < 10−5) and OS (HR: 0.53, p= 0.01). ELN intermediate group 2: (52 autologous and 93 unrelated donors). The outcome was identical. We conclude that good risk patients get higher benefit from autologous transplantation. Intermediate risk 2 patients have the same outcome and Intermediate risk 1 patients get higher benefit from unrelated donor transplants. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/ajh.24904

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.